All In Biotech

Drug Trial Radar · NCT00247962

Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis

A Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Etanercept and Sulphasalazine in Subjects With Ankylosing Spondylitis

Last checked: Nov 20, 2026Latest source record: Nov 8, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 566 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

566

Actual

Start

Dec 2005

Primary completion

Feb 2008

Study completion Feb 2008

Sponsor

Sponsor type
Industry
First posted
Nov 2, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy of etanercept and sulphasalazine in the treatment of Ankylosing Spondylitis.

Conditions

  • Ankylosing Spondylitis

Interventions

  • etanerceptDrug

    50 mg

  • sulphasalazine (SSZ)Drug

    Sulphasalazine: The target dose for SSZ is 1.5 g (3 tablets) twice daily orally. Subject start the oral TA at 0.5 g daily for the first week and increase by 0.5 g every week until a daily dose of 3 g. Is achieved by the start of study week 5 of the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS 20)Time frame: 16 weeks

Locations

83 sites in 18 countries. Site status is shown where the registry gives one.

  • Site not named

    Heidelberg West, Victoria, Australia

  • Site not named

    Shenton Park, Western Australia, Australia

  • Site not named

    Innsbruck, Austria

  • Site not named

    Klagenfurt, Austria

  • Site not named

    Linz, Austria

  • Site not named

    Beijing, China

  • Site not named

    Shanghai, China

  • Site not named

    Ostrava, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Frederiksberg, Denmark

  • Site not named

    Kolding, Denmark

  • Site not named

    Odense, Denmark

  • Site not named

    Vejle, Denmark

  • Site not named

    Helsinki, Finland

  • Site not named

    Kuopio, Finland

  • Site not named

    Tampere, Finland

  • Site not named

    Amiens, France

  • Site not named

    Bordeaux, France

  • Site not named

    Boulogne-Billancourt, France

  • Site not named

    Créteil, France

  • Site not named

    Marseille, France

  • Site not named

    Nantes, France

  • Site not named

    Orléans, France

  • Site not named

    Pierre Mendès, France

  • Site not named

    Toulouse, France

  • Site not named

    Berlin, Germany

  • Site not named

    Berlin, Germany

  • Site not named

    Erlangen, Germany

  • Site not named

    Gommern, Germany

  • Site not named

    Hamburg, Germany

  • Site not named

    Herne, Germany

  • Site not named

    Heubnerweg, Germany

  • Site not named

    Hildesheim, Germany

  • Site not named

    München, Germany

  • Site not named

    Pirna, Germany

  • Site not named

    Ratingen, Germany

  • Site not named

    Wiesbaden, Germany

  • Site not named

    Wiesbaden, Germany

  • Site not named

    Debrecen, Hungary

  • Site not named

    Győr, Hungary

Showing 40 of 83 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.